ENO Bio strictly adheres to innovative drug R&D and production processes, integrating the "Fundamental Layer" and "Technology Layer" capabilities. By comprehensively applying AI-driven drug design, mRNA engineering, delivery and formulation, CMC, and biological evaluation, ENO Bio assists partners in developing end-to-end solutions across infectious diseases, oncology, rare diseases, autoimmune disorders, metabolic diseases, and other therapeutic areas.
The following are selected collaboration case studies:
Therapeutic Area POC Product Mechanism of Action Development Status
Infectious Diseases Monkeypox mRNA Vaccine Active Immunization PCC
Staphylococcus aureus mRNA Vaccine Active Immunization LEAD
Herpes Simplex mRNA Vaccine Active Immunization LEAD
Chronic Hepatitis B Therapeutic mRNA Vaccine Active Immunization PCC
Lyophilized Rabies mRNA Vaccine Active Immunization LEAD
Oncology Multi-Cytokine mRNA Drug for Oncology Immunomodulation IND
Personalized Cancer mRNA Vaccine Active Immunization IIT
Universal Cancer mRNA Vaccine Active Immunization IIT/IND
Hematological Malignancy mRNA Therapy CAR-T HIT
Rare Diseases ATTR mRNA Drug Gene Editing PCC
Hemophilia A (FVIII) mRNA Drug Protein Supplementation PCC
Propionic Acidemia mRNA Drug Protein Supplementation LEAD
21-Hydroxylase Deficiency mRNA Drug Gene Editing LEAD
自身免疫性疾病 Membranous Nephropathy mRNA Therapy In Vivo CAR PCC
Systemic Lupus Erythematosus Therapy In Vivo CAR PCC
Desensitization mRNA Therapy Immunomodulation PCC
代谢疾病 Hypercholesterolemia mRNA Drug (PCSK9 Target) Gene Editing HIT
Hyperlipoproteinemia mRNA Drug (LP(a) Target) Gene Editing HIT
Hyperuricemia mRNA Drug (Urate Oxidase Target) Protein Supplementation LEAD
Other Disease Degenerative Osteoarthritis mRNA Drug (Dual-Target) Protein Supplementation LEAD
Novel Analgesic mRNA Drug (Nav1.7 Target) Protein Supplementation LEAD
Acne Treatment mRNA Drug Active Immunization LEAD
Diabetic Foot Treatment mRNA Drug Protein Supplementation HIT
Anti-Aging mRNA Drug Protein Supplementation HIT
Some partners: